| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,361,000 |
| Market
Cap: |
722.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.25 - $15.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mchugh Julie |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
9,850 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
20,050 |
|
- |
|
| Croarkin Richard |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
9,850 |
|
- |
|
| Mcdonnell Peter J |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
1,750 |
|
- |
|
| Mcgraw Benjamin F III |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
11,550 |
|
- |
|
| Gryska David W |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
5,250 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2021-02-23 |
4 |
D |
$15.66 |
$6,421 |
D/D |
(410) |
353,937 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2021-02-23 |
4 |
D |
$15.66 |
$11,949 |
D/D |
(763) |
86,709 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-23 |
4 |
D |
$15.66 |
$5,136 |
D/D |
(328) |
264,469 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2021-02-23 |
4 |
D |
$15.66 |
$26,622 |
D/D |
(1,700) |
233,396 |
|
- |
|
| Larocca John |
General Counsel |
• – – |
2021-02-19 |
4 |
D |
$15.95 |
$24,595 |
D/D |
(1,542) |
40,437 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-15 |
4 |
D |
$16.41 |
$11,897 |
D/D |
(725) |
264,797 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-15 |
4 |
OE |
$0.20 |
$11,888 |
D/D |
60,651 |
265,522 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2021-02-08 |
4 |
D |
$17.72 |
$16,320 |
D/D |
(921) |
354,347 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2021-02-08 |
4 |
D |
$17.72 |
$19,226 |
D/D |
(1,085) |
87,472 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-08 |
4 |
D |
$17.72 |
$11,802 |
D/D |
(666) |
204,871 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2021-02-08 |
4 |
D |
$17.72 |
$44,300 |
D/D |
(2,500) |
235,096 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2021-02-07 |
4 |
D |
$17.68 |
$19,006 |
D/D |
(1,075) |
355,268 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2021-02-07 |
4 |
D |
$17.68 |
$21,729 |
D/D |
(1,229) |
88,557 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-07 |
4 |
D |
$17.68 |
$12,394 |
D/D |
(701) |
205,537 |
|
- |
|
| Larocca John |
General Counsel |
• – – |
2021-02-07 |
4 |
D |
$17.68 |
$12,482 |
D/D |
(706) |
41,979 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2021-02-07 |
4 |
D |
$17.68 |
$44,129 |
D/D |
(2,496) |
237,596 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2021-02-06 |
4 |
D |
$17.68 |
$20,951 |
D/D |
(1,185) |
356,343 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2021-02-06 |
4 |
D |
$17.68 |
$25,424 |
D/D |
(1,438) |
89,786 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-06 |
4 |
D |
$17.68 |
$15,488 |
D/D |
(876) |
206,238 |
|
- |
|
333 Records found
|
|
Page 3 of 14 |
|
|
